» Articles » PMID: 11259652

Prevention and Elimination of Upper Respiratory Colonization of Mice by Group A Streptococci by Using a Bacteriophage Lytic Enzyme

Overview
Specialty Science
Date 2001 Mar 22
PMID 11259652
Citations 229
Authors
Affiliations
Soon will be listed here.
Abstract

Bacteriophage lytic enzymes quickly destroy the cell wall of the host bacterium to release progeny phage. Because such lytic enzymes specifically kill the species in which they were produced, they may represent an effective way to control pathogenic bacteria without disturbing normal microflora. In this report, we studied a murein hydrolase from the streptococcal bacteriophage C(1) termed lysin. This enzyme is specific for groups A, C, and E streptococci, with little or no activity toward several oral streptococci or other commensal organisms tested. Using purified lysin in vitro, we show that 1,000 units (10 ng) of enzyme is sufficient to sterilize a culture of approximately 10(7) group A streptococci within 5 seconds. When a single dose of lysin (250 units) is first added to the oral cavity of mice, followed by 10(7) live group A streptococci, it provides protection from colonization (28.5% infected, n = 21) compared with controls without lysin (70.5% infected, n = 17) (P < 0.03). Furthermore, when lysin (500 units) was given orally to 9 heavily colonized mice, no detectable streptococci were observed 2 h after lysin treatment. In all, these studies show that lysin represents a unique murein hydrolase that has a rapid lethal effect both in vitro and in vivo on group A streptococci, without affecting other indigenous microorganisms analyzed. This general approach may be used to either eliminate or reduce streptococci from the upper respiratory mucosal epithelium of either carriers or infected individuals, thus reducing associated disease.

Citing Articles

The Unique Capability of Endolysin to Tackle Antibiotic Resistance: Cracking the Barrier.

Sabur A, Khan A, Borphukan B, Razzak A, Salimullah M, Khatun M J Xenobiot. 2025; 15(1).

PMID: 39997362 PMC: 11856723. DOI: 10.3390/jox15010019.


Recombinant design of the enzymatically active domain of phage Enc34 endolysin to improve its activity against Gram-negative bacteria.

Kazaka T, Zrelovs N, Akopjana I, Bogans J, Jansons J, Dislers A FEMS Microbiol Lett. 2024; 371.

PMID: 39673269 PMC: 11657235. DOI: 10.1093/femsle/fnae103.


Identification of cell wall binding domains and repeats in phage endolysins: A molecular and diversity analysis.

Khan T, Mondal S, Mahmud A, Karim D, Draper L, Hill C Biochem Biophys Rep. 2024; 40:101844.

PMID: 39483175 PMC: 11525621. DOI: 10.1016/j.bbrep.2024.101844.


Characterization of a Peptidoglycan-Degrading Protein: Biochemical and Antimicrobial Characteristics, Antibiotic Synergism, and Delivery System Innovation.

Oliveira V, Rosa-Garzon N, Rocha A, Monteiro R, Goncalves Y, Kravicz M Probiotics Antimicrob Proteins. 2024; .

PMID: 39412595 DOI: 10.1007/s12602-024-10374-5.


Discovery and characterization of a novel LysinB from F2 sub-cluster mycobacteriophage RitSun.

Arora R, Nadar K, Bajpai U Sci Rep. 2024; 14(1):18073.

PMID: 39103410 PMC: 11300654. DOI: 10.1038/s41598-024-68636-9.


References
1.
Loessner M, Wendlinger G, Scherer S . Heterogeneous endolysins in Listeria monocytogenes bacteriophages: a new class of enzymes and evidence for conserved holin genes within the siphoviral lysis cassettes. Mol Microbiol. 1995; 16(6):1231-41. DOI: 10.1111/j.1365-2958.1995.tb02345.x. View

2.
Pichichero M . Group A beta-hemolytic streptococcal infections. Pediatr Rev. 1998; 19(9):291-302. DOI: 10.1542/pir.19-9-291. View

3.
Olivier C . Rheumatic fever--is it still a problem?. J Antimicrob Chemother. 2000; 45 Suppl:13-21. DOI: 10.1093/jac/45.suppl_1.13. View

4.
Raina J . Purification of Streptococcus group C bacteriophage lysin. J Bacteriol. 1981; 145(1):661-3. PMC: 217323. DOI: 10.1128/jb.145.1.661-663.1981. View

5.
Krause R . Studies on bacteriophages of hemolytic streptococci. I. Factors influencing the interaction of phage and susceptible host cell. J Exp Med. 1957; 106(3):365-84. PMC: 2136776. DOI: 10.1084/jem.106.3.365. View